Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

194 result(s)

  • Saint-Cloud
    IMMUNO-BIL (D48-1 PRODIGE 57)
    Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study

  • Thymic tumors
    Paris
    IMMUNO-TET
    Characterisation of the immune infiltrate and molecular features of Thymic Epithelial Tumours (TETs).

    CLEMENCE BASSE

  • Childhood and adolescent cancers
    Paris
    INFORM2 - NIVENT (IC 2018-07)
    INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies

    GUDRUN SCHLEIERMACHER

  • Thyroid cancer
    Saint-Cloud
    INTERMEDIATE-01
    Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy

    CAPUCINE RICHARD

  • Saint-Cloud
    IONESCO (IFCT-1601)
    A Phase II Prospective Immune Neoadjuvant Therapy Study of Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    IROCAS - PRODIGE 52
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

  • Paris
    LCB-1801-001
    A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.

    EMANUELA ROMANO

  • Paris, Saint-Cloud
    LE DECLIC-EPRI (IC 2019-06)
    DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.

    EVELYNE RENAULT TESSIER

  • Childhood and adolescent cancers
    Paris
    LYNPARZA (D0816C000025)
    A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours

    ISABELLE AERTS GAJDOS

  • Saint-Cloud
    M20-621
    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    MAPAM-01
    Therapeutic Nipple Areola Skin-sparing Mastectomy.

    EUGENIE GUILLOT

  • Saint-Cloud
    MCLA-128-CL01
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  • Saint-Cloud
    MCLA-128-CL02
    Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

    FRANCOIS-CLEMENT BIDARD

  • Thyroid cancer
    Saint-Cloud
    MIBI-THYR
    Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

    CAPUCINE RICHARD

  • Saint-Cloud
    MIRASOL
    MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK-4280A-008
    Phase 3 Randomized Clinical Study of MK-4280A (coformulated;favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus PhysicianÀs Choice;Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma;(KEYFORM-008).

    Adrien GILBERT

  • Saint-Cloud
    MK3475 B96 ENGOT ov65
    A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK3475-826 (Keynote-826)
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

  • Bladder cancer
    Paris
    MK3475-992
    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    MK7902-009 (LEAP-009)
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

    CHRISTOPHE LE TOURNEAU

  • Breast cancer
    Paris, Saint-Cloud
    MONDRIAN
    Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study

    FRANCOIS-CLEMENT BIDARD

  • Paris
    MOST Plus
    My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    MS100070-0087
    Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.

    FRANCOIS DOZ

  • Saint-Cloud
    MS200647-0020/BREAST020
    A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MUCILA
    Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease.

    CAMILLE CORDERO

  • Lung cancer
    Paris
    MYTX-011-01
    MYTX-011-01 : A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer · KisMET-01

    NICOLAS GIRARD

  • Lymphoma
    Saint-Cloud
    MorningLyte
    This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.

    CLEMENTINE SARKOZY

  • Saint-Cloud
    NANORAD2
    Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.

  • Breast cancer
    Saint-Cloud
    NEOVAB
    Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    NIVOPOST-OP / GORTEC 2018-01
    A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

    CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC

<
1 ...7
>